{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:07:52Z","timestamp":1779084472245,"version":"3.51.4"},"reference-count":15,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ritlecitinib, an oral covalent Janus kinase 3 (JAK3)\/TEC inhibitor, is now used for alopecia areata (AA), but pragmatic early\u2010on\u2010treatment markers to guide continuation decisions are needed. We evaluated whether the Week\u201012 (W12) change in Severity of Alopecia Tool (\u0394SALT) predicts Week\u201024 (W24) response in real\u2010world care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a single\u2010center observational cohort of consecutive patients with moderate\u2010to\u2010severe AA treated with ritlecitinib 50\u2009mg once daily. Assessments occurred at baseline (V0,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200977) and W12 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200955), W24 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200932), W36 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), W48 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911), W60 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097). The primary endpoint was the proportion achieving SALT \u2264\u200920 at W24. Secondary endpoints included SALT trajectory, clinician\u2010reported outcomes (ClinRO) for eyebrows\/eyelashes, patient\u2010reported outcomes (HADS, Skindex\u201016), and safety\/laboratories. Exploratorily, we tested \u0394SALT V0 to W12 as a predictor of W24 response using receiver operating characteristic\/area under the curve (ROC\/AUC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median SALT declined from 90.0 (V0) to 70.0 (W12) and 30.0 (W24); intra\u2010individual median \u0394SALT vs. baseline was \u221210.0 at W12 and \u221245.0 at W24. Responders (SALT \u2264\u200920) were 18.2% at W12 (10\/55) and 43.8% at W24 (14\/32). Periocular ClinRO improved by W24 in 54.5% (eyebrows) and 36.4% (eyelashes). Patient\u2010reported outcomes improved from W12 to W24. Safety was favorable: No serious adverse events or dose modifications were reported; adverse events were mostly mild to moderate (e.g., headache, acne, upper respiratory tract infection [URTI]\/nasopharyngitis), and laboratory panels remained stable with modest lipid increases. Early \u0394SALT robustly discriminated W24 outcomes: Median \u221241.0 in future responders vs. +3.0 in non\u2010responders with an AUC\u2009=\u20090.875. \u0394SALT at W12 also predicted sustained response at W48 (AUC 0.83). In multivariable analysis, \u0394SALT remained independently associated with W24 response (odds ratio [OR] 1.52 per 10\u2010point decrease).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In routine practice, ritlecitinib produced rapid, clinically meaningful improvement with good tolerability. The on\u2010treatment \u0394SALT at 12\u2009weeks is a pragmatic predictor of 24\u2010week success and supports a treat\u2010to\u2010target checkpoint to inform continuation\/optimization decisions alongside ClinRO and PROs.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/ijd70462-gra-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijd.70462","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:43:41Z","timestamp":1779083021000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early On\u2010Treatment Change in\n                    <scp>SALT<\/scp>\n                    as a Pragmatic Predictor of Ritlecitinib Response in Moderate\u2010To\u2010Severe Alopecia Areata: A Real\u2010World Cohort Study"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8390-4467","authenticated-orcid":false,"given":"Giuseppe","family":"Gallo","sequence":"first","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences University of Turin  Turin Italy"},{"name":"School of Dermatology and Venereology, Department of Medical Sciences University of Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isotta Giunipero","family":"di Corteranzo","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-9586","authenticated-orcid":false,"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1655-0395","authenticated-orcid":false,"given":"Francois","family":"Rosset","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/NRDP.2017.11"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/BJD.18883"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/BJD\/LJAF189"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.955035"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/JCPH.2347"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)00222\u20102"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40257\u2010024\u201000846\u20103"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40257\u2010023\u201000808\u20101"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.064"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/BJD.21696"},{"key":"e_1_2_9_12_1","unstructured":"\u201cWMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Participants \u2013 WMA \u2013 The World Medical Association\u201d."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201009\u20103267"},{"key":"e_1_2_9_14_1","unstructured":"\u201cData protection under GDPR \u2010 Your Europes\u201d."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/PDE.15378"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/CED\/LLAF312"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.70462","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:43:42Z","timestamp":1779083022000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.70462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":15,"alternative-id":["10.1111\/ijd.70462"],"URL":"https:\/\/doi.org\/10.1111\/ijd.70462","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]},"assertion":[{"value":"2025-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ijd.70462"}}